The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy
The dysregulation of sialic acid is closely associated with oncogenesis and tumor progression. Most tumor cells exhibit sialic acid upregulation. Sialic acid-binding immunoglobulin-like lectins (Siglecs) are receptors that recognize sialic acid and are expressed in various immune cells. The activity...
Gespeichert in:
| Veröffentlicht in: | Cancers 2024-01, Vol.16 (2), p.289 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 289 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Feng, Haokang Feng, Jiale Han, Xu Ying, Ying Lou, Wenhui Liu, Liang Zhang, Lei |
| description | The dysregulation of sialic acid is closely associated with oncogenesis and tumor progression. Most tumor cells exhibit sialic acid upregulation. Sialic acid-binding immunoglobulin-like lectins (Siglecs) are receptors that recognize sialic acid and are expressed in various immune cells. The activity of Siglecs in the tumor microenvironment promotes immune escape, mirroring the mechanisms of the well-characterized PD-1/PD-L1 pathway in cancer. Cancer cells utilize sialic acid-linked glycans to evade immune surveillance. As Siglecs exhibit similar mechanisms as the established immune checkpoint inhibitors (ICIs), they are potential therapeutic targets for different forms of cancer, especially ICI-resistant malignancies. Additionally, the upregulation of sialic acid serves as a potential tumor biomarker. This review examines the feasibility of using sialic acid and Siglecs for early malignant tumor detection and discusses the potential of targeting Siglec-sialic acid interaction as a novel cancer therapeutic strategy. |
| doi_str_mv | 10.3390/cancers16020289 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2917866810</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A780872883</galeid><sourcerecordid>A780872883</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-daf9d059004741ea8685a4018325aa5d275273c29a8459590e3f674ad573253</originalsourceid><addsrcrecordid>eNptkctPGzEQxq2KqkEpZ27IUi9cQrx-rO1jQH0gIYFE7qvBO5sadu3U3j3kv8cJ9IWwDx6Nf9_MaD5CTit2IYRlSwfBYcpVzTjjxn4gx5xpvqhrK4_-iWfkJOdHVo4Qla71JzIThiupDTsm3fon0rs4Yhg99DR29N5venSZQmhLDL13dOV8WxKZXvo4QHoqTQ_fRZtgi9NYmDWkDY6Z-kDX0xATvR6GKcTxgOw-k48d9BlPXt85uf_2dX31Y3Fz-_36anWzcFKIcdFCZ1umLGNSywrB1EaBZJURXAGolmvFtXDcgpHKFg5FV2sJrdKFEHNy_lJ1m-KvCfPYDD477HsIGKfccFtpU9emYgX98gZ9jFMKZbY9ZZSUzOq_1AZ6bHzo4pjA7Ys2q7I-o7kxolAX71Dltjh4FwN2vuT_EyxfBC7FnBN2zTb5sthdU7Fmb23zxtqiOHsdd3oYsP3D_zZSPAMZEJzM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2918544097</pqid></control><display><type>article</type><title>The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Feng, Haokang ; Feng, Jiale ; Han, Xu ; Ying, Ying ; Lou, Wenhui ; Liu, Liang ; Zhang, Lei</creator><creatorcontrib>Feng, Haokang ; Feng, Jiale ; Han, Xu ; Ying, Ying ; Lou, Wenhui ; Liu, Liang ; Zhang, Lei</creatorcontrib><description>The dysregulation of sialic acid is closely associated with oncogenesis and tumor progression. Most tumor cells exhibit sialic acid upregulation. Sialic acid-binding immunoglobulin-like lectins (Siglecs) are receptors that recognize sialic acid and are expressed in various immune cells. The activity of Siglecs in the tumor microenvironment promotes immune escape, mirroring the mechanisms of the well-characterized PD-1/PD-L1 pathway in cancer. Cancer cells utilize sialic acid-linked glycans to evade immune surveillance. As Siglecs exhibit similar mechanisms as the established immune checkpoint inhibitors (ICIs), they are potential therapeutic targets for different forms of cancer, especially ICI-resistant malignancies. Additionally, the upregulation of sialic acid serves as a potential tumor biomarker. This review examines the feasibility of using sialic acid and Siglecs for early malignant tumor detection and discusses the potential of targeting Siglec-sialic acid interaction as a novel cancer therapeutic strategy.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16020289</identifier><identifier>PMID: 38254780</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Acids ; Antigens ; B cells ; Biomarkers ; Cancer ; Cells ; Clinical trials ; Cytokines ; Development and progression ; Enzymes ; Health aspects ; Immune checkpoint inhibitors ; Immune evasion ; Immunosurveillance ; Immunotherapy ; Kinases ; Lectins ; Ligands ; Lymphocytes ; Malignancy ; Monoclonal antibodies ; Organic acids ; Ovarian cancer ; PD-1 protein ; PD-L1 protein ; Phosphatase ; Phosphorylation ; Polysaccharides ; Recruitment ; Self-recognition ; Sialic acids ; Signal transduction ; Therapeutic targets ; Tumor cells ; Tumor microenvironment ; Tumorigenesis ; Tumors ; Up-regulation</subject><ispartof>Cancers, 2024-01, Vol.16 (2), p.289</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-daf9d059004741ea8685a4018325aa5d275273c29a8459590e3f674ad573253</citedby><cites>FETCH-LOGICAL-c433t-daf9d059004741ea8685a4018325aa5d275273c29a8459590e3f674ad573253</cites><orcidid>0000-0002-0238-543X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38254780$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Feng, Haokang</creatorcontrib><creatorcontrib>Feng, Jiale</creatorcontrib><creatorcontrib>Han, Xu</creatorcontrib><creatorcontrib>Ying, Ying</creatorcontrib><creatorcontrib>Lou, Wenhui</creatorcontrib><creatorcontrib>Liu, Liang</creatorcontrib><creatorcontrib>Zhang, Lei</creatorcontrib><title>The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>The dysregulation of sialic acid is closely associated with oncogenesis and tumor progression. Most tumor cells exhibit sialic acid upregulation. Sialic acid-binding immunoglobulin-like lectins (Siglecs) are receptors that recognize sialic acid and are expressed in various immune cells. The activity of Siglecs in the tumor microenvironment promotes immune escape, mirroring the mechanisms of the well-characterized PD-1/PD-L1 pathway in cancer. Cancer cells utilize sialic acid-linked glycans to evade immune surveillance. As Siglecs exhibit similar mechanisms as the established immune checkpoint inhibitors (ICIs), they are potential therapeutic targets for different forms of cancer, especially ICI-resistant malignancies. Additionally, the upregulation of sialic acid serves as a potential tumor biomarker. This review examines the feasibility of using sialic acid and Siglecs for early malignant tumor detection and discusses the potential of targeting Siglec-sialic acid interaction as a novel cancer therapeutic strategy.</description><subject>Acids</subject><subject>Antigens</subject><subject>B cells</subject><subject>Biomarkers</subject><subject>Cancer</subject><subject>Cells</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Development and progression</subject><subject>Enzymes</subject><subject>Health aspects</subject><subject>Immune checkpoint inhibitors</subject><subject>Immune evasion</subject><subject>Immunosurveillance</subject><subject>Immunotherapy</subject><subject>Kinases</subject><subject>Lectins</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Malignancy</subject><subject>Monoclonal antibodies</subject><subject>Organic acids</subject><subject>Ovarian cancer</subject><subject>PD-1 protein</subject><subject>PD-L1 protein</subject><subject>Phosphatase</subject><subject>Phosphorylation</subject><subject>Polysaccharides</subject><subject>Recruitment</subject><subject>Self-recognition</subject><subject>Sialic acids</subject><subject>Signal transduction</subject><subject>Therapeutic targets</subject><subject>Tumor cells</subject><subject>Tumor microenvironment</subject><subject>Tumorigenesis</subject><subject>Tumors</subject><subject>Up-regulation</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkctPGzEQxq2KqkEpZ27IUi9cQrx-rO1jQH0gIYFE7qvBO5sadu3U3j3kv8cJ9IWwDx6Nf9_MaD5CTit2IYRlSwfBYcpVzTjjxn4gx5xpvqhrK4_-iWfkJOdHVo4Qla71JzIThiupDTsm3fon0rs4Yhg99DR29N5venSZQmhLDL13dOV8WxKZXvo4QHoqTQ_fRZtgi9NYmDWkDY6Z-kDX0xATvR6GKcTxgOw-k48d9BlPXt85uf_2dX31Y3Fz-_36anWzcFKIcdFCZ1umLGNSywrB1EaBZJURXAGolmvFtXDcgpHKFg5FV2sJrdKFEHNy_lJ1m-KvCfPYDD477HsIGKfccFtpU9emYgX98gZ9jFMKZbY9ZZSUzOq_1AZ6bHzo4pjA7Ys2q7I-o7kxolAX71Dltjh4FwN2vuT_EyxfBC7FnBN2zTb5sthdU7Fmb23zxtqiOHsdd3oYsP3D_zZSPAMZEJzM</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Feng, Haokang</creator><creator>Feng, Jiale</creator><creator>Han, Xu</creator><creator>Ying, Ying</creator><creator>Lou, Wenhui</creator><creator>Liu, Liang</creator><creator>Zhang, Lei</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0238-543X</orcidid></search><sort><creationdate>20240101</creationdate><title>The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy</title><author>Feng, Haokang ; Feng, Jiale ; Han, Xu ; Ying, Ying ; Lou, Wenhui ; Liu, Liang ; Zhang, Lei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-daf9d059004741ea8685a4018325aa5d275273c29a8459590e3f674ad573253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acids</topic><topic>Antigens</topic><topic>B cells</topic><topic>Biomarkers</topic><topic>Cancer</topic><topic>Cells</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Development and progression</topic><topic>Enzymes</topic><topic>Health aspects</topic><topic>Immune checkpoint inhibitors</topic><topic>Immune evasion</topic><topic>Immunosurveillance</topic><topic>Immunotherapy</topic><topic>Kinases</topic><topic>Lectins</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Malignancy</topic><topic>Monoclonal antibodies</topic><topic>Organic acids</topic><topic>Ovarian cancer</topic><topic>PD-1 protein</topic><topic>PD-L1 protein</topic><topic>Phosphatase</topic><topic>Phosphorylation</topic><topic>Polysaccharides</topic><topic>Recruitment</topic><topic>Self-recognition</topic><topic>Sialic acids</topic><topic>Signal transduction</topic><topic>Therapeutic targets</topic><topic>Tumor cells</topic><topic>Tumor microenvironment</topic><topic>Tumorigenesis</topic><topic>Tumors</topic><topic>Up-regulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Feng, Haokang</creatorcontrib><creatorcontrib>Feng, Jiale</creatorcontrib><creatorcontrib>Han, Xu</creatorcontrib><creatorcontrib>Ying, Ying</creatorcontrib><creatorcontrib>Lou, Wenhui</creatorcontrib><creatorcontrib>Liu, Liang</creatorcontrib><creatorcontrib>Zhang, Lei</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Feng, Haokang</au><au>Feng, Jiale</au><au>Han, Xu</au><au>Ying, Ying</au><au>Lou, Wenhui</au><au>Liu, Liang</au><au>Zhang, Lei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>16</volume><issue>2</issue><spage>289</spage><pages>289-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>The dysregulation of sialic acid is closely associated with oncogenesis and tumor progression. Most tumor cells exhibit sialic acid upregulation. Sialic acid-binding immunoglobulin-like lectins (Siglecs) are receptors that recognize sialic acid and are expressed in various immune cells. The activity of Siglecs in the tumor microenvironment promotes immune escape, mirroring the mechanisms of the well-characterized PD-1/PD-L1 pathway in cancer. Cancer cells utilize sialic acid-linked glycans to evade immune surveillance. As Siglecs exhibit similar mechanisms as the established immune checkpoint inhibitors (ICIs), they are potential therapeutic targets for different forms of cancer, especially ICI-resistant malignancies. Additionally, the upregulation of sialic acid serves as a potential tumor biomarker. This review examines the feasibility of using sialic acid and Siglecs for early malignant tumor detection and discusses the potential of targeting Siglec-sialic acid interaction as a novel cancer therapeutic strategy.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38254780</pmid><doi>10.3390/cancers16020289</doi><orcidid>https://orcid.org/0000-0002-0238-543X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2024-01, Vol.16 (2), p.289 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2917866810 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Acids Antigens B cells Biomarkers Cancer Cells Clinical trials Cytokines Development and progression Enzymes Health aspects Immune checkpoint inhibitors Immune evasion Immunosurveillance Immunotherapy Kinases Lectins Ligands Lymphocytes Malignancy Monoclonal antibodies Organic acids Ovarian cancer PD-1 protein PD-L1 protein Phosphatase Phosphorylation Polysaccharides Recruitment Self-recognition Sialic acids Signal transduction Therapeutic targets Tumor cells Tumor microenvironment Tumorigenesis Tumors Up-regulation |
| title | The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T10%3A47%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Potential%20of%20Siglecs%20and%20Sialic%20Acids%20as%20Biomarkers%20and%20Therapeutic%20Targets%20in%20Tumor%20Immunotherapy&rft.jtitle=Cancers&rft.au=Feng,%20Haokang&rft.date=2024-01-01&rft.volume=16&rft.issue=2&rft.spage=289&rft.pages=289-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16020289&rft_dat=%3Cgale_proqu%3EA780872883%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2918544097&rft_id=info:pmid/38254780&rft_galeid=A780872883&rfr_iscdi=true |